Cyprus biotech firm sees losses widen to €3.46m

Cyprus-based biotechnology company iDNA Genomics Public Ltd on Monday announced that it approved its audited consolidated financial statements for 2025, reporting a wider loss and a sharp deterioration in its balance sheet compared with the previous year.
The company’s board approved its annual report and audited consolidated financial statements for the year ended December 31, 2025, prepared in accordance with applicable legislation and accounting standards....
This is a summary. Read the full article at Cyprus Mail.
Read full article


